| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Runt-related transcription factor 2;Acute myeloid leukemia 3 protein;Core-binding factor subunit alpha-1;CBF-alpha-1;Oncogene AML-3;Osteoblast-specific transcription factor 2;OSF-2;Polyomavirus enhancer-binding protein 2 alpha A subunit;PEA2-alpha A;PEBP2-alpha A;SL3-3 enhancer factor 1 alpha A subunit;SL3/AKV core-binding factor alpha A subunit;RUNX2;AML3, CBFA1, OSF2, PEBP2A; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | A synthetic peptide corresponding to a sequence in the middle region of human RUNX2, identical to the related rat and mouse sequences. |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-RUNX2 Antibody Picoband® is an antibody targeting RUNX2. Common applications include WB, IHC, Flow Cytometry, ELISA. Key specifications include host: Rabbit; clonality: Polyclonal; isotype: Rabbit IgG; reactivity: Human,Mouse,Rat; observed MW: 62 kDa; calculated MW: 56648 MW.
Boster Bio Anti-RUNX2 Antibody catalog # PA1224. Tested in WB applications. This antibody reacts with Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
Key elements and design rationale
- Target: RUNX2 — Runt-related transcription factor 2
- Antibody format: Host: Rabbit; Clonality: Polyclonal; Isotype: Rabbit IgG
- Species reactivity: Human,Mouse,Rat
- Molecular weight guidance: Observed: 62 kDa; Calculated: 56648 MW
Specificity note: No cross reactivity with other proteins.
Biological background
Protein function (datasheet): Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'- PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1 (I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation. .
Scientific background (datasheet): Core binding factor A1 (CBFA1/RUNX2) is a runt-like transcription factor essential for osteoblast differentiation. This protein is a member of the RUNX family of transcription factors and has a Runt DNA-binding domain. It is essential for osteoblastic differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and regulatory factors involved in skeletal gene expression. D'Souza et al. (1999) indicate a non-redundant role for Cbfa1 in tooth development that may be distinct from that in bone formation. In odontogenesis, Cbfa1 is not involved in the early signaling networks regulating tooth initiation and early morphogenesis but regulates key epithelial-mesenchymal interactions that control advancing morphogenesis and histodifferentiation of the epithelial enamel organ.
Cellular localization (datasheet): Nucleus.
Tissue details (datasheet): Specifically expressed in osteoblasts.
Sequence similarities (datasheet): Contains 1 Runt domain.
Research relevance and current trends
- Commonly studied in contexts related to Cancer,Chromatin Binding Proteins,Developmental Biology,DNA/RNA Binding,Epigenetics and Nuclear Signaling,Hematopoietic Progenitors,Mesenchymal Stem Cells,Neurogenesis,Neurology Process,Neuroscience,Oncoproteins,Oncoproteins/Suppressors,Organogenesis,Skeletal Development,Stem Cells,Transcription,Transcription Factors.
- Supports comparative expression analysis across conditions, genotypes, or treatments when paired with appropriate controls.
- Useful for confirming target presence and subcellular distribution using orthogonal readouts (e.g., microscopy vs. immunoblotting).
Common research applications
- Western blot (WB): Compare relative target abundance and apparent size/isoforms across samples; interpret bands in light of expected MW and potential PTMs.
- ELISA: Measure target abundance in compatible matrices using a standard-curve readout; ensure dilution linearity and appropriate controls.
- Immunohistochemistry (IHC): Assess tissue distribution and cell-type patterns; interpret staining with appropriate negative controls and antigen context.
- Flow cytometry: Quantify target-positive populations in single-cell suspensions; pair with viability and isotype/FMO controls conceptually.
Notes for experimental interpretation
- Consider isoforms, post-translational modifications, and processing that can shift apparent molecular weight or localization.
- Cross-reactivity (datasheet): No cross-reactivity with other proteins
- Use appropriate positive and negative controls (e.g., KO/KD, blocking peptide, or isotype controls) to support specificity interpretation.
As a polyclonal antibody, this reagent may recognize multiple epitopes on the target, which can improve detection robustness but may require careful specificity controls.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.